Bristol-Myers Squibb heads into its April 30 Q1 earnings call with an unusual combination — short sellers are quietly rebuilding positions, options traders are leaning more optimistic than usual, and the Street holds a constructive consensus above the current price.
The short-side story is more noise than conviction. At 1.44% of the free float, short interest is low enough that the bear trade is not a defining feature of the setup. It has climbed roughly 8% over the past week to around 29.4 million shares — a meaningful jump in percentage terms — but this follows a sharp drop in late April after the stock pulled back nearly 17% from its month-ago peak. With availability well above any danger threshold, borrow conditions are essentially unrestricted. The cost to borrow ticked up to 0.42% on Tuesday but has spent most of the past month below 0.50%, and the ORTEX short score of 30.3 places BMY in the least-pressured tier of pharmaceutical names. Lending market availability is loose — there is no squeeze dynamic in play.
Options positioning tells a more interesting story. Call activity has picked up relative to puts, pushing the put/call ratio down to 0.88 — roughly 1.4 standard deviations below its 20-day average of 0.92. That is the most call-tilted reading BMY has produced in recent weeks, and it stands in notable contrast to the cautious options setups seen across much of the pharma sector ahead of earnings. Whether this reflects genuine conviction or simple call speculation, the options market is positioned less defensively than the price action alone might suggest. The stock closed at $58.26 on Tuesday, down about 2% on the week and barely changed over a month.
The Street is constructively positioned on BMY, though not uniformly so. The mean analyst target of $63.04 implies around 8% upside from Tuesday's close. Bulls — including Piper Sandler and Barclays, both at Overweight with $75 targets — anchor their cases on BMY's leadership in immuno-oncology, its strong US revenue base representing roughly 70% of total sales, and the pathway toward estimated annual revenues of roughly $47 billion for 2026. B of A Securities trimmed its target a dollar to $67 on April 9 while keeping its Buy rating intact, a signal that even the cautious adjustments are not structural bear turns. More neutral voices at Citigroup and Cantor Fitzgerald cite revenue concentration risk and competitive pressure in core franchises. With a P/E of 9.4x, an EV/EBITDA of 8.7x, and a forward dividend yield near 4.4%, the valuation is not demanding — the stock ranks in the 99th percentile on dividend score and carries an EV/EBIT rank in the 78th percentile, reflecting a business generating substantial cash.
The one genuine wrinkle is the CFO's recent open-market sales. David Elkins sold roughly $1.85 million of stock on April 1 at prices between $61.60 and $62.05 — modest in absolute terms and assigned low trade significance scores, but worth noting given that shares have since retreated to $58.26. CEO Christopher Boerner sold a smaller parcel around the same time. These look more like routine tax-related disposals than a directional signal, but the timing — ahead of earnings and after a period of outperformance — keeps them on the radar. The 90-day insider net figure is modestly positive at around $4.4 million when awards and sales are combined.
Close peers had a softer week. PFE dropped 3% over the past five sessions and AZN fell more than 4.5%, suggesting sector-level headwinds that BMY's own relative resilience (-1.9% on the week) has partially absorbed. The Q1 print on April 30 is the next inflection point — the previous earnings release in late April moved the stock down 2.1% the following day, though the February release produced a 7.6% single-session gain. The range of recent outcomes is wide, and Thursday's call will be the clearest test of whether the call-heavy options positioning and the Street's constructive consensus are correctly calibrated.
See the live data behind this article on ORTEX.
Open BMY on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
